About CPF
Company Profiles
Awards
Global Collaboration
Media Center
Subsidiary
Products & Services
API and intermediates
Dosage
Services
R&D
News
Company News
Industry News
Contact Us
中
About CPF
Products & Services
R&D
News
Contact Us
API and intermediates
Dosage
Services
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
No.
Dosage
Strength
Indication
1
Relugolix
Anhydrous Non-solvent Form
17-19kg
2
Remdesivir
3
Resmetirom
Form I and Form λ
40-50 kg
4
Rimegepant Sulfate
Form H1.5-1
8-12 kg
5
Rivaroxaban
Form Ⅰ
140-150kg
6
Rosuvastatin Calcium
Amorphous
205kg-225kg
7
Rosuvastatin Calcium Tablets
5mg/10mg/20mg/40mg
Hypercholesterolemia
8
Ruxolitinib Phosphate
As Innovator
14-17kg
1